Conor faces litigation from Boston and Angiotech
This article was originally published in Clinica
Boston Scientific and Angiotech Pharmaceuticals, the Canadian company from which Boston exclusively licenses its paclitaxel stent-coating technology, have filed a joint lawsuit against Conor Medsystems in the Netherlands. Vancouver-based Angiotech launched the legal action against Menlo Park, California-based Conor after obtaining a favourable decision on its European patent No 0706,376 on January 24.
You may also be interested in...
Guidelines outline permitted practices and patient safeguards for both physicians and technology platforms.
Executives at Pfizer and Moderna expressed confidence in their US government partners for initial COVID-19 vaccine distribution and expect pediatric studies to begin before the end of the year. Regeneron will “do the right thing” in pricing its antibody cocktail.
Takeda's acquisition of Shire fueled the company into a top 10 pharma company in the latest Scrip 100 rankings, as other mega-mergers are set to shape the leaderboard in the future.